Beam Therapeutics Inc.
BEAM · XNASCIK 1745999fmd_0HJKSRHRY825TT2H1WZA2GFZ8NManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 52 | 61 | 378 | 64 | 140 |
| Research and development | 55 | 103 | 387 | 312 | 437 | 368 | 410 |
| Total operating expenses | 75 | 133 | 444 | 399 | 554 | 479 | 523 |
| Operating income | (75) | (133) | (392) | (338) | (176) | (416) | (384) |
| Interest and investment income | – | – | – | 15 | 47 | 49 | 44 |
| Other non-operating income (expense) | (3) | (62) | 22 | 78 | 45 | 39 | 304 |
| Income before taxes | – | (195) | (371) | (260) | (131) | (377) | (80) |
| Income tax expense | 0 | 0 | 0 | 3 | 1 | 0 | 0 |
| Net income from continuing operations | – | (195) | (371) | (264) | (133) | (377) | (80) |
| Net income | (78) | (195) | (371) | (289) | (133) | (377) | (80) |
| Net income to common shareholders | (91) | (196) | (371) | (289) | (133) | (377) | (80) |